RxDoctor Payments Data

Marc Greenstein, DO

Urology · Atlanta, GANPI 1154383743

Payments from drug & device makers

$10,263in general payments, 2019–2025

Across 271 payments — averaging $37.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$2K
  • Teleflex LLC$1K
  • Medtronic$939
  • Myriad Genetic Laboratories, Inc.$565
  • Endo Pharmaceuticals Inc.$480
  • Boston Scientific$414
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$3503%
  • Travel & lodging$1,34513%
  • Food & beverage$8,40482%
  • Education$1632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,263 in reported general payments places this provider in the 75th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$391,185
Medicare patients
654
Services billed
7,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide21$305,400
OrgovyxRelugolix44$117,082
MyrbetriqMirabegron122$90,073
GemtesaVibegron88$63,629
XyostedTestosterone Enanthate16$13,744
Methenamine Hippurate186$8,551
Abiraterone Acetate18$7,606
Solifenacin Succinate74$5,228
Alfuzosin Hcl ErAlfuzosin Hcl306$5,078
Estradiol41$4,776
Finasteride384$4,335
YuvafemEstradiol28$3,250
Potassium Citrate ErPotassium Citrate22$2,437
Tamsulosin Hcl185$1,935
Testosterone17$1,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$50$305,40021 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$406$180,711132 claims
Astellas Pharma US IncMyrbetriq$392$90,073122 claims
Antares Pharma, Inc.Xyosted$161$13,74416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 369 urology providers in Georgia.

Other urology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →